Overview of Dr. Yang
Dr. Jay Yang is an oncologist in Detroit, MI and is affiliated with multiple hospitals in the area, including Karmanos Cancer Center, DMC Harper University Hospital, and DMC - Detroit Receiving Hospital. He received his medical degree from University of Michigan Medical School and has been in practice 19 years. Dr. Yang accepts several types of health insurance, listed below. He is one of 73 doctors at Karmanos Cancer Center and one of 43 doctors at DMC Harper University Hospital who specialize in Oncology.
Education & Training Providence Hospital and Medical Centers Fellowship, Hematology/Oncology, 2008 - 2011 Providence Hospital and Medical Centers Residency, Internal Medicine, 2005 - 2008 Providence Hospital and Medical Centers Internship, Transitional Year, 2004 - 2005 University of Michigan Medical School Class of 1998 Certifications & Licensure Clinical Trials Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 01 Kanate, A.S.,Tolentino, A.R.,Menter, A.,Bseiso, A.W.,Conlin, A.K.,Sehgal, A.R.,Karnad, A.B.,Klein, A.K.,Mato, A.R.,Vemula, A.Y.,Shipstone, A.,Kasimis, B.S.,Holkova, B.,Marchello, B.T.,Friday, B.E.,DiCarlo... A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2013 Dec 01 Jennifer Woyach A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 01 DiStefano, A.,Saleh, A.,Alencar, A.,Lewis, A.,Klein, A.,Shaw, A.,Shustov, A.,Forero-Torres, A.,Fredrichs, A.M.,Amin, B.,Lau, C.,Morningstar, C.,Wood, C.,Farber, C.,Simone, C.D.,Hagenstad, C.,Houde, C.,Jon... Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects >or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2012 Mar 01 Goldberg, S.,O'Brien, S.M.,Prasad, L.,Weiner, H.,Wu, N. Publications & Presentations PubMed
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or ...
Talha Badar, Aniko Szabo, Shira Dinner, Michaela Liedtke, Madelyn Burkart, Rory M. Shallis, Ilana R. Yurkiewicz, Eric Kuo, Muhammad Ali Khan, Suresh Kumar Balasubraman...> ;Cancer. 2020 Dec 1
High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma.
AliM Gabali, Feras Zaiem, Rada Jerbi, Omar Albanyan, Jordyn Puccio, Zyad Kafri, Jay Yang> ;Avicenna journal of medicine. 2020 Oct 13
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
Talha Badar, Aniko Szabo, Martha Wadleigh, Michaela Liedtke, Shukaib Arslan, Caitlin Siebenaller, Ibrahim Aldoss, Elizabeth Schultz, Mehrdad Hefazi, Mark R. Litzow, Er...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Mar 19 Join now to see all Abstracts/Posters Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with... Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019 Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic... Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019 A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Na¥ve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive... Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019 Join now to see all Lectures FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study 2018 ASH Annual Meeting - San Diego, CA - 12/1/2018 Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) 2018 ASH Annual Meeting - San Diego, CA - 12/1/2018 Insurance Accepted
Aetna Choice POS II
BCBS Blue Card PPO BCBS Illinois PPO CIGNA HMO CIGNA Open Access CIGNA PPO First Health PPO
Great West PPO
Humana ChoiceCare Network PPO Multiplan PHCS PPO Multiplan PPO PriorityHealth HMO United Healthcare - Direct Choice Plus POS United Healthcare - Direct Options PPO Please verify your coverage with the provider's office directly when scheduling an appointment